Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Opdivo (nivolumab) Market Size Outlook: How Quickly Will Revenue Expand Through 2030?
The opdivo (nivolumab) market has experienced significant growth in recent years. It is anticipated to expand from $8.34 million in 2025 to $9.01 million in 2026, at a compound annual growth rate (CAGR) of 8.1%. The increase observed in previous periods can be linked to the approval of PD-1 inhibitors, the growing worldwide prevalence of cancer, the inherent drawbacks of chemotherapy, impressive clinical trial results, and the increasing acceptance of immunotherapy by oncologists.
The market for opdivo (nivolumab) is projected to experience robust expansion over the coming years, reaching $12.13 million in 2030, demonstrating a compound annual growth rate (CAGR) of 7.7%. This anticipated growth during the forecast period is driven by factors such as the expansion into new oncology indications, the proliferation of combination therapy protocols, a rise in biomarker-based patient selection, an increase in cancer diagnosis rates, and enhanced oncology healthcare expenditure. Key trends observed throughout the forecast timeframe encompass the expanding application of immune checkpoint inhibitors, a growing embrace of combination immunotherapy regimens, the advancement of PD-1 based cancer treatments, broader utilization across numerous cancer indications, and a concentrated effort on achieving long-term survival outcomes.
Get A Free Sample Report With In-Depth Market Insights:
Opdivo (nivolumab) Market Expansion Drivers: What’s Shaping Future Growth?
The Opdivo (nivolumab) market is expected to experience growth driven by the increasing occurrence of non-small cell lung cancer (NSCLC). This type of lung cancer is the most common, making up approximately 85% of all lung cancer cases. The rising incidence of NSCLC is largely attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo operates by blocking the PD-1 receptor on immune cells, thereby strengthening the body’s immune system to detect and attack cancer cells. For example, the American Cancer Society, a US-based health organization, reported that in 2024, there were 234,580 new lung cancer diagnoses in the US, with 80% being non-small cell lung cancer (NSCLC), which represented an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Thus, the growing incidence of non-small cell lung cancer is propelling the expansion of the Opdivo (nivolumab) market.
Opdivo (nivolumab) Market Breakdown By Product Type And Application
The opdivo (nivolumab) market covered in this report is segmented –
1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL
2) By Dosage: Injection, Solution, Other Dosages
3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
4) By End-User: Hospitals, Clinics, Other End Users
Opdivo (nivolumab) Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies in the Opdivo (nivolumab) market are concentrating on developing advanced combination therapies. The aim is to improve treatment effectiveness, overcome resistance mechanisms, and broaden their applications across various cancer types. This combination therapy involves the strategic use of Opdivo (nivolumab) along with other agents, such as chemotherapy, to provide a more comprehensive treatment approach for patients with advanced cancer. For example, in October 2024, the Food and Drug Administration, a US-based federal agency, approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment. This is to be followed by single-agent nivolumab as adjuvant therapy after surgery for adults with resectable non-small cell lung cancer who do not have known EGFR or ALK mutations. This authorization permits Opdivo to be administered both before and after surgical procedures, thereby enhancing therapeutic outcomes for eligible patients.
Opdivo (nivolumab) Market Company Landscape And Competitive Strategy
Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical
View The Full Opdivo (nivolumab) Market Report:
Opdivo (nivolumab) Market Geographic Spread And Regional Opportunities
North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model